Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SGP meets reduced EPS estimates

Schering-Plough (SGP) reported second quarter EPS of $0.12, meeting the Street's consensus,

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE